HomeALK-B • CPH
add
ALK-Abello A/S
Previous close
kr 205.20
Day range
kr 204.80 - kr 207.60
Year range
kr 130.70 - kr 210.20
Market cap
41.77B DKK
Avg Volume
176.16K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 1.53B | 11.14% |
Operating expense | 620.00M | 2.82% |
Net income | 263.00M | 30.85% |
Net profit margin | 17.22 | 17.70% |
Earnings per share | — | — |
EBITDA | 450.00M | 35.95% |
Effective tax rate | 24.86% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 509.00M | 21.19% |
Total assets | 8.27B | 17.42% |
Total liabilities | 2.42B | 14.06% |
Total equity | 5.85B | — |
Shares outstanding | 221.19M | — |
Price to book | 7.76 | — |
Return on assets | 11.39% | — |
Return on capital | 14.52% | — |
Cash Flow
Net change in cash
| (DKK) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 263.00M | 30.85% |
Cash from operations | 320.00M | 23.55% |
Cash from investing | -104.00M | -6.12% |
Cash from financing | -209.00M | -533.33% |
Net change in cash | -8.00M | -106.20% |
Free cash flow | 159.75M | 66.41% |
About
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
Founded
1923
Website
Employees
2,782
